Slovak trial on cardiovascular risk reduction following national guidelines with CaDUET® (the STRONG DUET study)

Advances in Therapy

Volumn 30, Issue 1, 2013, Pages 60-70

  Fedacko, Jan ^a   Pella, Daniel ^a   Jarcuska, Peter ^a   Sabol, Frantisek ^b   Kmec, Jan ^c   Lopuchovsky, Tomas ^a   Merkovska, Lucia ^a   Jedlickova, Lucia ^a   Janicko, Martin ^a   Sajty, Matej ^a  

^a L PASTEUR UNIVERSITY HOSPITAL   (Slovakia)

^b Department of Cardiac Surgery   (Slovakia)

^c JA Reimans Faculty Hospital   (Slovakia)

Author keywords

Amlodipine; Atorvastatin; Blood pressure; Cardiology; Cardiovascular risk; Hypertension; Low density lipoprotein cholesterol; Slovakia

Indexed keywords

AMLODIPINE PLUS ATORVASTATIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; AMLODIPINE; AMLODIPINE, ATORVASTATIN DRUG COMBINATION; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; HEPTANOIC ACID DERIVATIVE; PYRROLE DERIVATIVE; DRUG COMBINATION;

ADULT; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOLOGIST; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; FEMALE; HUMAN; HYPERTENSION; INTERNIST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; OBSERVATIONAL STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RISK REDUCTION; SLOVAKIA; AGED; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG COMBINATION; HYPERLIPIDEMIA; MIDDLE AGED; RISK FACTOR; TREATMENT OUTCOME; CARDIOVASCULAR DISEASES; HYPERLIPIDEMIAS;

AGED; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; DRUG COMBINATIONS; FEMALE; HEPTANOIC ACIDS; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; HYPOLIPIDEMIC AGENTS; MALE; MIDDLE AGED; PYRROLES; RISK FACTORS; SLOVAKIA; TREATMENT OUTCOME;

EID: 84891537357     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-012-0075-z     Document Type: Article

References (22)

1. Müller-Nordhorn J, Binting S, Roll S, Willich SN. An update on regional variation in cardiovascular mortality within Europe. Eur Heart J. 2008;29:1316-26.
2. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Eur J Cardiovasc Prev Rehabil. 2007;14(Suppl. 2):S1-113.
3. Chobanian AV, Bakris GL, Black HR, et al.; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA. 2003;289:2560-72.
4. Mancia G, de Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2007;28:1462-536.
5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97.
6. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systemic review and meta-analysis. BMJ. 2003;326:1423-9.
7. Turnbull F. Effects of different blood-pressure- lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362:1527-35.
8. Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension. 2004;43:10-7.
9. Steinberg BA, Bhatt DL, Mehta S, et al. Nine-year trends in achievement of risk factor goals in the US and European outpatients with cardiovascular disease. Am Heart J. 2008;156:719-27.
10. Avdicova M, Hruba F, Namesna J. Surveillance chronických chorôb na Slovensku, 1st Edition Výskyt rizikových faktorov srdcovo cievnych a nádorových ochoreni v modelovej oblasti Banská Bystrica v r. 1993-2003 a v modelovej oblasti Trebiśov v r. 1998-2003; 37-57. In Slovak. Available at: http://www.vzbb.sk/sk/projekty/ cindi-sk.pdf. Accessed Dec 3 2012.
11. Hobbs FDR, Gensini G, Mancini GBJ, et al.; JEWEL Study Group. Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? Rationale and design for an international, openlabel program to assess the effectiveness of a single pill (amlodipine/atorvastatin) to attain recommended target levels for blood pressure and lipids (The JEWEL Program). Int J Cardiol. 2006;110:242-50.
12. Conroy R, Pyorala K, Fitzgerald AP, et al.; SCORE Project Group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: The SCORE project. Eur Heart J. 2003;24:987-1003.
13. Gomez-Belda A, Rodilla E, González C, Costa JA, Serra B, Pascual JM. Lipid lowering goals in high risk and very high cardiovascular risk patients: a reasonable challenge? Rev Clin Esp. 2006;206:417-21. In Spanish
14. Blank R, LaSalle J, Reeves R, Maroni J, Tarasenko L, Sun F. Single-pill therapy in the treatment of concomitant hypertension and dyslipidemia (the amlodipine/atorvastatin Gemini study). J Clin Hypertens. 2005;7:264-73.
15. Flack JM, Victor R,Watson K, et al. Improved attainment of blood pressure and cholesterol goals using single pill amlodipine/atorvastatin in African Americans: the CAPABLE trial. Mayo Clin Proc. 2008;83:35-45.
16. Erdine S, Ro YM, Tse H-F, et al.; Gemini-AALA Investigators. Single-pill amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study). J Hum Hypertens. 2008;23:196-210.
17. Perk J, De Backer G, Gohlke I, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012:33;1635-701.
18. Preston RA, Harvey P, Herfert O, et al. A randomized, placebo-controlled trial to evaluate the efficacy, safety, and pharmacodynamic interaction of coadministered amlodipine and atorvastatin in 1660 patients with concomitant hypertension and dyslipidemia: the Respond trial. J Clin Pharmacol. 2007;47:1555-69.
19. Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med. 2003;165:1147-52.
20. Nichol MB, Patel BV, Thiebaud P, et al. A single pill combining antihypertensive and statin therapies improves patient adherence compared with multidrug combinations: results from the CaDUET Adherence Research program and Education (CARPE) - PBM Adherence Study. J Clin Hypertens. 2006;8:456.
21. Sever PS, Dahlof B, Poulter NR, et al.; ASCOT Investigators. Prevention of coronary and19. Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med. 2003;165:1147-52. stroke events with atorvastatin in hypertensive patients who have average or lower-than- average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149-58.
22. Messerli FH, Bakris GL, Ferrera D, et al.; ANALON Investigators. Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial. J Clin Hypertens (Greenwich). 2006;8:571-81.